INTRODUCTION
Studies of cell cycle kinetics and of nucleotide incorporation into the DNA of various tissues are important for understanding normal and malignant cell growth (1) . Tritiated thymidine incorporation into DNA de-tected by autoradiography has been used to study the cell kinetics of normal and malignant cells in vivo and in vitro (1, 2) . Bromodeoxyuridine (BUdR),' a pyrimidine analogue of thymidine, produces significant xray sensitization following incorporation into DNA (3) . Clinical trials using BUdR showed enhanced x-ray sensitivity of human tumors (4) (5) ; however, it has not been possible to directly demonstrate BUdR incorporation into normal or malignant cells. As part of a clinical investigation evaluating BUdR as an in vivo x-ray sensitizer (5), we used a monoclonal antibody and immunohistochemistry to measure BUdR incorporation into the DNA of normal and malignant cells. This technique could quantitate the proportion of normal and malignant cells incorporating BUdR during the period of infusion and, therefore, the proportion of cells dividing (i.e., labeling index). This immunohistochemical technique was also used to detect BUdR in the chromosomes of marrow cells and for the first time directly demonstrate the phenomenon of sister chromatid exchange (SCE) (6) in man in vivo.
METHODS

Therapy of patients and procurement of human specimens
Tumor and normal tissue specimens were obtained from patients treated with BUdR in a study at the National Cancer Institute. Written informed consent was obtained before ' Abbreviations used in this paper: BUdR, bromodeoxyuridine; SCE, sister chromatid exchanges. 1:200) , and stained with an avidin-biotin-peroxidase complex (8) . Visualization of the reaction product was achieved with the diaminobenzidine-H202 reaction as previously described (8) . Cells that contained BUdR were identified by the presence of a dark pigment over their nuclei.
Normal and malignant human tissue. Biopsies of normal skin and two malignant melanomas were obtained before and after treatment; frozen sections were prepared and stained as described above or with hematoxylin and eosin.
Incorporation of BUdR into chromosomes. Marrow cells from patients receiving BUdR infusions were incubated in 0.5 ,ug/ml of colchicine for 1 h, followed by treatment with hypotonic PBS (0.02 M) and fixation in methanol and acetic acid (3:1). The chromosomes were treated with 0.1 N hydrochloric acid and allowed to air-dry. The slides were then stained with the monoclonal anti-BUdR antibody and the immunohistochemical procedure described previously. 25 metaphase chromosomes were examined from one patient. In a parallel study, chromosomes were also stained with a technique used previously to identify BUdR incorporation into chromosomes in vitro and based on differential chromatid staining following exposure to Hoechst 33258 and Giemsa (9).
Measurement of blood levels of BUdR
Blood levels were assayed using a high-performance liquid chromatography technique (manuscript submitted for publication).
RESULTS
BUdR incorporation into V79 cells. As a preliminary study to test the feasibility of this technique, Chinese hamster ovary V79 cells were cultured in 10' or 10-6 M BUdR or no BUdR for 17 h. BUdR was detected in these cells both by a fluorescent antibody technique ( Fig. 1 A) and by immunohistochemical staining ( Fig. 1 B-D BUdR incorporation into human cells. Tumor and normal tissue specimens were obtained from patients treated with BUdR as a radiosensitizer in a study at the National Cancer Institute. One patient (Fig. 2 ) was exposed to a constant blood level of BUdR for 8 d. A marrow biopsy was obtained and chromosome preparations were made. The chromosomes were stained with the immunohistochemical technique (Fig. 2) . Chromosomes in 25/25 metaphases had darkly stained chromatids, therefore suggesting they had incorporated BUdR. There was no background staining with the second antibody alone and chromosomes obtained from cells before therapy with BUdR did not bind the antibody and therefore did not stain. Several of the chromosomes displayed differential chromatid staining (Fig.  2) Hoechst stain and Giemsa technique to stain the chromosomes from the same patient also demonstrated differential chromatid staining, confirming the presence of BUdR in these chromosomes (data not shown).
The immunohistochemical staining method (Fig. 3 ) revealed that after in vivo infusion, BUdR was present in the nuclei of 10-50% of human malignant cells and in the basal layer of cells of the normal epidermis. Biopsies from two malignant melanomas were obtained before and after in vivo exposure to blood levels of 1-2 X 10-6 M BUdR for 8 (Fig. 3 A-C) and 13 (Fig.  3 D-F) d. Frozen sections were stained as described or with hematoxylin and eosin. The first tumor consisted of small nodules (0.5 cm' in size). There was no staining of any cells in the tissue biopsies obtained before treatment with BUdR (Fig. 3, panel A) This immunohistochemical technique was then used to identify BUdR in tissue biopsies obtained before and after therapy. As expected, it was found that BUdR had been extensively incorporated into both malignant and normal cells following in vivo administration. Distribution of cells that had incorporated BUdR was relatively uniform in the small malignant melanoma nodules examined. However, the distribution of cells that had incorporated BUdR in the large melanoma was more heterogeneous, with 10-50% of the cells containing BUdR in different portions of the tumor. Variation in the labeling of this tumor was consistent with previous findings using [3H]thymidine in vivo in large tumor masses (2) . The variability of proliferation in different portions of the tumor may be due to differences in perfusion.
The finding of large portions of the tumor with no BUdR suggests that only some of the cells in a tumor can be sensitized to radiation by BUdR. BUdR was also found in normal cells, confirming that it is not a selective radiosensitizer for malignant cells, although it is possible the extent of sensitization of tumor cells may be greater if they incorporate more BUdR.
In skin, the greatest incorporation of BUdR was seen in the basal layer of the epidermis, which is consistent with this being the site of highest cell proliferation. There was also significant incorporation into skin adnexal structures, such as sebaceous glands. More proliferation was seen in the normal epidermal cells overlying the tumor than in epidermal cells from other sites.
The incorporation of BUdR into normal skin and into the normal proliferating cells in the marrow demonstrated directly in this study for the first time is not surprising. In addition to x-rays, BUdR also sensitizes cells to UV light (10) and to fluorescent light (unpublished observations) and so its presence in the normal epidermis is consistent with the skin phototoxicity observed when patients are treated with BUdR. BUdR is cytotoxic at high concentrations (3) and therefore the incorporation of BUdR into normal cells in the bone marrow probably produces the fall in blood counts often observed and the enhanced radiation sensitivity of marrow progenitor cells (11) . The mechanism(s) by which BUdR sensitizes cells to UV light and causes cytotoxicity are not totally understood. It has been shown that photoproducts resulting from bromine radicals, as well as uracil radicals, transiently exist (12) . The injury from these products can result in both singleand double-strain breaks in DNA (12) . The etiology of cytotoxicity resulting from substitution of thymidine by BUdR may result from interference with the function of DNA (13) .
BUdR in chromosomes in the marrow after in vivo infusion allowed us to demonstrate for the first time that in man SCE occur in vivo. In vivo SCE has previously been reported using animal systems (14, 15) . Although the significance between SCE elevation and exposure to a variety of mutagens is uncertain, there appears to be a relationship (16) . Our method should allow for the study of in vivo SCE induction following chemotherapeutic agents (that are also mutagens) in selected patients.
There are several advantages to the technique we described over those of [3H]thymidine for in vivo cell kinetic studies in man. Since most studies of this nature have been conducted in a clinical setting, the use of [3H]thymidine for cell kinetic studies has involved exposure to a potentially hazardous radioactive compound in addition to the prescribed therapy. In our study, BUdR itself is a major part of the therapy and therefore cell kinetic studies can be conducted without introducing additional procedures. Although we have found significant but readily reversible toxicity to bone marrow and skin using a prolonged infusion (5), it is quite possible that important kinetic information can be obtained with a shorter, less toxic infusion. Studies are planned with infusion periods for only 1-2 d. Although BUdR is a known mutagen (17), a short infusion in selected patient populations may allow for in vivo studies of chromosome replication and cell kinetics in a variety of chronic diseases. Secondly, in vivo [3H]thymidine studies in man are cumbersome, timeconsuming (up to months for autoradiograph storage), and, due to low levels of isotope incorporation, the interpretation of autoradiographs can often times be difficult. The BUdR technique we describe is rapid and easily interpreted with a minimum of background staining. The recently renewed clinical interest in BUdR as an x-ray sensitizer (5) provides a good opportunity to reexamine human malignant and normal cell kinetics in vivo. Our approach, based on the detection of BUdR by immunohistochemistry, may have BUdR in Tumors and Chromosomes Detected with a Monoclonal Antibody 
